Amarin Decision Could Spur Pressure Against FDA On Supplement Claim Policy
This article was originally published in The Tan Sheet
Executive Summary
First Amendment advocate Jonathan Emord says the industry bows to FDA “intimidation” in not making truthful claims for their products. But the federal district court ruling for Amarin is the latest decision to strike against FDA’s policy on regulating supplement label claims, he says.
You may also be interested in...
Omega-3 Petition Seeks Unqualified Blood Pressure, CHD Claims
The trade group Global Organization for EPA and DHA Omega-3 petitions FDA for an unqualified health claim related to reduced blood pressure as a surrogate marker for coronary heart disease risk.
Selenium Claim Ruling Forces FDA's Hand, May Clear Path For More QHCs
A court decision obligating FDA to reconsider a slate of qualified health claims for selenium could compel the agency to allow more QHCs for dietary supplements
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.